newsfilter
← Latest News
Business Wire·

Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement

– Data Support the Study of RLYB116 as a Potential Best-In-Class Therapeutic for Multiple Complement Mediated Diseases – – Initiation of RLYB116 Phase 2 Clinical Trial in Immune Platelet Transfusion Refractoriness